Dear Reader,
Gold has shattered records, soaring past $3,800 an ounce...
His research shows it could be triggered by a major event, eerily similar to what happened in the 1970s.
It's NOT inflation, fed rate cut expectations, escalating geopolitical tensions, or anything you're likely expecting.
And Doc believes you MUST own shares of his top gold stock.
He says you could 10x your money without touching a risky miner or a boring exchange-traded fund.
It's the centerpiece of Doc's full gameplan for this wild market, with extraordinary upside potential.
Click here for the full details on this developing gold story.
Regards,
Matt Weinschenk
Director of Research, Stansberry Research
Is Abbott's January Pullback a Good Time to Buy?
Authored by Thomas Hughes. Article Posted: 1/24/2026.
What You Need to Know
- Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories (NYSE: ABT)'s January 2026 pullback has made the stock look attractively valued. The move—driven more by market angst than by company-specific weakness—appears to be a knee-jerk overreaction that has pushed the shares back into the buy zone.
Don't be fooled by bread and games (Ad)
The former CEO of Google calls it the most important thing to happen in 500, maybe 1,000 years of human society. A former U.S. Treasury Secretary says when your great-grandchildren write the history of this period, the political headlines will be the second or third story. The first story is something none of us have seen before. The dot-com collapse, global financial crisis, and COVID-19 pandemic don't compare to what's coming next. We may be entering a period of dramatic, almost unimaginable change.
See the full warning and how to prepare now.This buy zone lines up with the 2022–2024 trading range, when Abbott was recovering from a post–COVID-19 revenue contraction and institutions were actively accumulating shares.
Abbott Laboratories Growth Accelerates
The most that can be said about Abbott's Q4 results and guidance is that some metrics missed market expectations. Still, revenue of $11.46 billion was up 4.5% year-over-year, margins improved, and adjusted earnings grew at an accelerated pace.
Revenue growth missed by several hundred basis points, but margin strength offset much of the shortfall: adjusted earnings per share (EPS) rose 12%, slightly above consensus.
By segment, the results highlighted the strength of Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted—Nutrition down nearly 9%—but that weakness was offset by solid growth in Established Pharmaceuticals and Med Tech.
Established Pharmaceuticals grew about 9%, driven by generics and emerging markets, while Med Tech rose 12.3% with broad-based strength. Margins improved as well, though they landed a bit below some analyst forecasts.
A shift in product mix toward higher-margin Med Tech, reduced COVID-19-related sales and operational improvements helped drive margin expansion. Management expects earnings to improve roughly 10% in 2026, outpacing revenue growth and supporting the company's capital-return plans.
Abbott's capital returns are a central part of the investment case. The company is a Dividend King, having increased its payout for more than 50 consecutive years, and its payout ratio is below 50% of consensus EPS, leaving room for share buybacks. Buybacks can help offset the dilutive impact of share-based compensation while supporting total shareholder return; the stock yields about 2.5% after the decline.
Analysts Point to Robust Rebound in Abbott Laboratories Stock
Some analysts noted the revenue shortfall, but there were no major rating or price-target cuts the morning of the earnings release. The prevailing view is that this fundamentally healthy company can continue returning capital while reinvesting for growth, and the longer-term outlook remains constructive.
MarketBeat's consensus share price target implies up to roughly 30% upside, potentially putting the stock back near all-time highs; even the lower-end targets suggest some positive upside from current levels.
Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, margin expansion and strategic acquisitions. The acquisition of Exact Sciences, for example, would broaden revenue and profit streams and expand Abbott's product pipeline.
That said, the recent sell-off has been steep and further downside is possible. Institutions accumulated shares through 2025 and are likely buyers at these discounted levels, which could help stabilize the stock.
Early technical support appears near $105–$110, though it is not yet confirmed. Downside risk could push shares toward the low end of the buy zone—around $95 or below—before any sustained rebound.
This email is a sponsored message provided by Stansberry Research, a third-party advertiser of MarketBeat. Why did I get this email content?.
This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Stansberry Research please click here.
If you need help with your account, please email MarketBeat's South Dakota based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Place, Suite 620, Sioux Falls, South Dakota 57103-7078. USA..
0 Response to "The next biggest bull run in over 50 years"
Post a Comment